TIDES USA 2026 Conference Set for May 11–14 Boston, Featuring Bachem, Gilead, Novo Nordisk on Peptide and Oligonucleotide CMC + GMP Capacity
TIDES USA 2026 — the year's leading oligo, peptide, and mRNA therapeutics conference — opens May 11–14 in Boston, with six concurrent scientific tracks and 200+ presentations. Programmatic highlights include CMC strategy for complex dual and triple agonists under regulatory scrutiny, defining defensible starting materials for GLP-1 APIs, and how CDMOs are securing scarce GMP suite capacity dominated by big-pharma volume contracts. Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk teams are scheduled to speak — the same week as Hims & Hers' Q1 print and within the new AJMC oral-peptides public-facing news cycle.